title: Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia.
abstract: OBJECTIVE
  Dose dependent response of cervical intraepithelial neoplasia (CIN) to topically administered interferon (IFN) gamma was assessed and compared with conventional laser therapy.
  
  
  METHODS
  33 women were included in a randomized phase II trial which was double blinded for IFN dosages. Twenty-four patients received IFN gamma-1 beta gel and a control group of nine patients was treated with laser surgery. 18 patients had smears suggesting CIN II and 15 patients had smears suggesting CIN III. The response was assessed 6 months after starting of IFN gamma-1 beta treatment or having laser surgery.
  
  
  RESULTS
  Topical IFN gamma-1 beta treatment gave a cure rate of 42% independent of IFN dosage as compared to an 89% cure rate with laser therapy (P = 0.02). Patients with CIN II responded better compared with patients with CIN III. Current smokers showed a significantly lower cure rate whereas use of oral contraceptives (OC) did not influence response. High viral load with high risk types of human papillomaviruses (HPV) was associated with a better response.
authors.affiliation: Department of Obstetrics and Gynecology, University of Ulm, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Schneider
authors.forename: T
authors.initials: T
authors.lastname: Grubert
authors.forename: R
authors.initials: R
authors.lastname: Kirchmayr
authors.forename: D
authors.initials: D
authors.lastname: Wagner
authors.forename: U
authors.initials: U
authors.lastname: Papendick
authors.forename: G
authors.initials: G
authors.lastname: Schlunck
mesh_terms: D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage*; D053685:Laser Therapy; D009367:Neoplasm Staging; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000628:therapy*
chemical_list: D005782:Gels; D011994:Recombinant Proteins; D007371:Interferon-gamma